

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jun 2026

A comparative study of the effect of two drugs, atorvastatin and glucophage, on plasma insulin resistance and follicular fluid changes (the amount of antioxidants and oocyte growth factors) in women with polycystic ovary syndrome.

Protocol summary

BMP15 and GDF9 levels in granulosa cells

Study aim

A comparative study of the effect of two drugs, atorvastatin and glucophage, on plasma insulin resistance and follicular fluid changes (the amount of antioxidants and oocyte growth factors) in women with polycystic ovary syndrome.

Design

Clinical trial with a control group, randomized, phase 3 on 50 patients. The block method was used for randomization.

Settings and conduct

It was done in Zainbiah hospital in Shiraz and both groups took medicine orally for 6 weeks: the first group took 40 mg of atorvastatin every night after dinner, the second group took 500 mg of glucophage three times a day after meals.

Participants/Inclusion and exclusion criteria

Entry criteria: age 18-40 years, no thyroid disorder, Cushing's syndrome, hyperprolactinoma, no kidney disease, liver disease, diabetes, lipid profile disorder, no cardiovascular disease and blood pressure, no use of ovarian function stimulating drugs or hormonal drugs within 3 months. In the past, no use of insulin-sensitive drugs or lipid profile in the past 3 months, no smoking, no alcohol, no use of addictive substances, no breast cancer, no drug contraindications, no malabsorption, and minimal abnormal resistance to insulin. Exclusion criteria: Body mass more than 30 kg/m² and body mass less than 19 kg/m²

Intervention groups

50 random samples will be selected and divided into two treatment groups: atorvastatin or case group (25) and glucophage or control group (25 people)

Main outcome variables

The effect of two drugs, glucophage and atorvastatin, on plasma insulin resistance: follicular fluid antioxidants:

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20240122060763N1**

Registration date: **2024-02-01, 1402/11/12**

Registration timing: **prospective**

Last update: **2024-02-01, 1402/11/12**

Update count: **0**

Registration date

2024-02-01, 1402/11/12

Registrant information

Name

Sanaz Alaei

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 71 3725 5699

Email address

alaei@sums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2024-02-22, 1402/12/03

Expected recruitment end date

2024-10-24, 1403/08/03

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

A comparative study of the effect of two drugs, atorvastatin and glucophage, on plasma insulin resistance and follicular fluid changes (the amount of antioxidants and oocyte growth factors) in women with polycystic ovary syndrome.

Public title

A comparative study of the effects of two drugs, atorvastatin and glucophage, on plasma insulin resistance and follicular fluid changes in women with polycystic ovary syndrome.

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

According to the Rotterdam criteria (the presence of two criteria for the diagnosis of polycystic ovaries 1- oligomenorrhea or amenorrhea 2- clinical or laboratory findings of hyperandrogenism 3- the presence of polycystic ovaries in ultrasound examination) the diagnosis of PCOS has been confirmed in them Age 18-40 years Absence of thyroid disorder, Cushing's syndrome, hyperprolactinoma Absence of kidney disease, liver disease, diabetes, lipid profile disorder No history of cardiovascular disease and blood pressure Not using ovarian stimulation drugs or hormonal drugs in the last 3 months Not using insulin-sensitive drugs or lipid profiles in the last 3 months not smoking non-alcoholic No use of addictive substances Not having breast cancer Absence of medicinal contraindications Absence of malabsorption Having a minimally abnormal amount of insulin resistance

Exclusion criteria:

Body mass more than 30 kg/m² Body mass less than 19 kg/m²

Age

From **18 years** old to **40 years** old

Gender

Female

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: **50**

Randomization (investigator's opinion)

Randomized

Randomization description

The random assignment method in this study will be permutation block method in such a way that A represents the person who receives the case and B represents the person who receives the control. receives This method is implemented by considering blocks of 2 so that the total number of possible binary permutations is equal to 2. 2 blocks including: AB and BA. The desired random list of 50 items, which includes 25 blocks of 2

items (total number of samples = 50 x 25) is generated and the order of allocation of each of the methods to the samples participating in the study is determined. The way to use the table of random numbers is that a starting point is randomly selected and 25 numbers are randomly selected (row or column) and the permutation assigned to each number is noted (the order of placement of the permutations next to each other from left to right will be to the right) and how to allocate all 50 people to two groups A and B will be determined.

Blinding (investigator's opinion)

Not blinded

Blinding description**Placebo**

Not used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee of Shiraz Medical Sciences

Street address

Faculty of Modern Sciences, Shiraz University of Medical Sciences

City

Shiraz

Province

Fars

Postal code

7154895379

Approval date

2024-01-08, 1402/10/18

Ethics committee reference number

IR.SUMS.REC.1402.444

Health conditions studied**1****Description of health condition studied**

Women with polycystic ovary syndrome

ICD-10 code

E28.2

ICD-10 code description**Primary outcomes****1****Description**

The amount of insulin resistance is measured based on the HOMA index. The amount of fasting insulin is multiplied by the amount of fasting sugar and the

resulting number is divided by 22.5, which is equal to 1 in normal people.

Timepoint

The amount of insulin resistance is measured once before the intervention in two groups and again after the intervention in two groups

Method of measurement

Measuring insulin resistance: the amount of fasting insulin is multiplied by the amount of fasting sugar and the resulting number is divided by 22.5, which is equal to 1 in normal people.

Secondary outcomes

1

Description

Changes of MDA (malon-di-aldehyde) in follicular fluid

Timepoint

After the intervention, it is measured in the follicular fluid and compared with the standard value

Method of measurement

Using a commercial measuring kit of malondialdehyde kiazist

2

Description

Examination of TAC (Total Antioxidant Capacity) in follicular fluid

Timepoint

After the intervention and comparison with the standard value

Method of measurement

Using a commercial kit to measure TAC is key

3

Description

Investigation of catalase changes in follicular fluid

Timepoint

After the intervention and comparison with the standard value

Method of measurement

Using the commercial kit for measuring catalase of Kiazist company

4

Description

Measuring changes in oocyte growth factor (GDF-9) in granulosa cells

Timepoint

After the intervention and comparison with the standard value

Method of measurement

Through the expression of the gene of this protein with the help of Realtime PCR

5

Description

Changes in oocyte growth factor (BMP15) in granulosa

cells

Timepoint

After the intervention and comparison with the standard value

Method of measurement

Through gene expression and Realtime PCR

Intervention groups

1

Description

Intervention group: Using atorvastatin in the amount of 40 mg every night after dinner for 6 weeks until the day of egg retrieval.

Category

Treatment - Drugs

2

Description

Control group: Taking 500 mg Glucophage 3 times a day after meals for 6 weeks until the day of egg retrieval.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Zainabiya Hospital

Full name of responsible person

Dr. Sanaz Alaei

Street address

Unit 6,Third Floor,Reza Building 4,AllModares Boulevard,Azadegan Boulevard,y 5,

City

Shiraz

Province

Fars

Postal code

7154895379

Phone

+98 917 109 4051

Email

Alaee@sums.ac.ir

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Shiraz University of Medical Sciences

Full name of responsible person

Dr. Mohammad Hashem Hashempour

Street address

Zand St., Central Building of Shiraz University of Medical Sciences, 7th floor, Research and Technology Deputy

City

Shiraz

Province

Fars

Postal code

7134814336

Phone

+98 71 3212 2430

Email

vcrdep@sums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Shiraz University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding*empty***Country of origin****Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Shiraz University of Medical Sciences

Full name of responsible person

Sanaz Alaei

Position

Assistant Professor

Latest degree

Ph.D.

Other areas of specialty/work

Reproductive Biology

Street addressModares Boulevard, Azadegan Boulevard, Alley 5,
Reza Building 4, 3rd floor**City**

Shiraz

Province

Fars

Postal code

7154895379

Phone

+98 71 3725 5699

Email

alaei@sums.ac.ir

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Shiraz University of Medical Sciences

Full name of responsible person

Dr. Sanaz Alaei

Position

Assistant Professor

Latest degree

Ph.D.

Other areas of specialty/work

Reproductive Biology

Street addressModares Boulevard, Azadegan Boulevard, Alley 5,
Reza Building 4, 3rd floor**City**

Shiraz

Province

Fars

Postal code

7154895379

Phone

+98 71 3725 5699

Email

Alaei@sums.ac.ir

Person responsible for updating data**Contact****Name of organization / entity**

Shiraz University of Medical Sciences

Full name of responsible person

Dr. Sanaz Alaei

Position

Assistant Professor

Latest degree

Ph.D.

Other areas of specialty/work

Reproductive Biology

Street addressModares Boulevard, Azadegan Boulevard, Alley 5,
Reza Building 4, 3rd floor**City**

Shiraz

Province

Fars

Postal code

7154895379

Phone

009837255699

Email

Alaei@sums.ac.ir

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

There is no further information

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available